First Outbreak of Human Infection with Avian Influenza A(H7N9) Virus in Guangxi, China, 2016 to 2017

0
0
0

First Outbreak of Human Infection with Avian Influenza A(H7N9) Virus in Guangxi, China, 2016 to 2017

The emergence of avian influenza A(H7N9) in China has posed significant public health challenges since its initial identification in Shanghai in March 2013. By September 2017, five epidemic waves had resulted in 1,564 laboratory-confirmed human cases, with an alarming fatality rate of approximately 40%. The fifth epidemic wave marked a critical shift in viral pathogenicity, as 4.09% of cases (31/758) were attributed to highly pathogenic avian influenza (HPAI) A(H7N9), signaling a transition from the previously dominant low pathogenic avian influenza (LPAI) strain. Guangxi, a southwestern Chinese province adjacent to Guangdong—a region with historically high H7N9 incidence—experienced its first major outbreak during the 2016–2017 epidemic season. This outbreak represented a dramatic departure from sporadic prior cases, with 27 confirmed human infections reported across ten of Guangxi’s 14 cities. This article examines the epidemiological, clinical, and environmental factors driving this outbreak, offering insights into prevention strategies and risk mitigation.

Epidemiological Profile of the Outbreak

The Guangxi outbreak spanned October 1, 2016, to June 9, 2017, with the first confirmed case imported from Guangdong Province. This index patient developed symptoms on January 27, 2017, and succumbed to the infection on February 15, 2017. The first locally acquired case emerged on February 18, 2017, followed by a rapid surge in infections. Among the 27 cases, the median age was 53 years (range: 12–77 years), with a pronounced male predominance (male-to-female ratio: 2.86). A majority of patients (81%, 22/27) resided in rural areas, and 96% (26/27) reported direct poultry exposure within ten days preceding symptom onset.

Exposure pathways were categorized into two primary routes: backyard poultry exposure (59%, 16/27) and occupational exposure (33%, 9/27), such as working in live poultry markets (LPMs) or poultry farming. Notably, 63% of patients initially sought care at private or village clinics, highlighting gaps in early diagnosis within rural healthcare systems. Delays in antiviral treatment were widespread: the median interval from symptom onset to first medical consultation was 1 day, but the median time to initiation of neuraminidase inhibitor therapy (e.g., oseltamivir) extended to 5 days.

Clinical Outcomes and Risk Factors for Mortality

The case-fatality rate reached 52% (14/27), exceeding rates reported in earlier epidemics. Comparative analysis of fatal versus non-fatal cases revealed critical risk factors:

  1. Chronic Comorbidities: Underlying conditions such as diabetes, hypertension, or chronic respiratory diseases were significantly associated with mortality (57% in fatal cases vs. 8% in survivors; P = 0.013). Adjusted odds ratios confirmed chronic diseases elevated mortality risk by 15.34-fold (95% CI: 1.50–156.91).
  2. Treatment Delays: While not statistically significant, fatal cases exhibited longer intervals to antiviral therapy (median: 6 days vs. 4 days in survivors; P = 0.128).
  3. Backyard Poultry Exposure: A higher proportion of fatal cases involved backyard poultry contact (71% vs. 46% in survivors; P = 0.252), suggesting potential links to high viral loads or delayed recognition of sick poultry.

All patients developed severe respiratory illness requiring hospitalization, underscoring the virulence of H7N9. Subtyping of viral strains identified 11 HPAI and 6 LPAI cases (remaining cases lacked sufficient samples for analysis). HPAI-infected patients reported more frequent exposure to sick or dead poultry (7/11 vs. 0/6; P = 0.035), though clinical outcomes (e.g., hospitalization duration, mortality) did not differ significantly between HPAI and LPAI groups.

Environmental Surveillance and Viral Transmission Dynamics

Active surveillance of LPMs—a known amplifier of avian influenza transmission—was intensified from February 2017. A total of 9,875 environmental samples (swabs from cages, chopping boards, poultry feces, and drinking water) were collected across Guangxi. Overall, 3.84% (379/9,875) tested positive for H7 RNA, with substantial regional variation:

  • Guilin: 14.29% positivity (85/595 samples)
  • Hechi: 13.49% (39/289)
  • Yulin: 13.39% (32/239)
  • Beihai: 0.70% (10/1,420)
  • Fangchenggang: 0.09% (2/2,144)

Temporal analysis revealed a surge in human cases between February 10 and March 21, 2017, coinciding with elevated H7 detection rates in LPMs (5.20%–11.82%). A strong positive correlation emerged between weekly case counts and H7 RNA positivity rates (R = 0.793, P < 0.05), implicating environmental contamination as a key driver of human infections.

Comparative Analysis with Guangdong Province

Guangxi’s outbreak shared similarities with neighboring Guangdong, a perennial H7N9 hotspot. Both regions reported rural predominance, backyard poultry exposure, and LPM-mediated transmission. However, Guangxi’s lower H7 positivity rate in LPMs (3.84% vs. higher rates in Guangdong) may partially explain its comparatively smaller case burden. Additionally, Guangxi’s healthcare infrastructure faced challenges in early case detection: all reported cases were severe, suggesting underdiagnosis of mild or asymptomatic infections.

Public Health Interventions and Lessons Learned

In response to the outbreak, Guangxi authorities implemented multipronged measures:

  1. LPM Closures: Temporary shutdowns of LPMs in high-incidence areas reduced human-poultry contact, mirroring successful strategies in Guangdong.
  2. Poultry Vaccination: Enhanced immunization of poultry flocks was prioritized to curb viral circulation.
  3. Public Awareness Campaigns: Targeted messaging in rural communities emphasized avoiding sick/dead poultry and promoting early medical consultation.

These measures likely contributed to the outbreak’s decline by mid-2017. However, persistent demand for live poultry in southern China and the asymptomatic nature of LPAI infections in poultry underscore ongoing risks.

Implications for Future Outbreak Management

  1. Early Antiviral Therapy: Reducing delays in oseltamivir administration—ideally within 48 hours of symptom onset—is critical to lowering mortality.
  2. Strengthened Surveillance: Expanding routine H7N9 testing in rural clinics and LPMs could improve early detection.
  3. Differentiating HPAI and LPAI: Rapid subtyping of H7N9 strains is essential, as HPAI’s potential for multidrug resistance and accelerated disease progression necessitates tailored responses.
  4. Chronic Disease Management: Integrating H7N9 awareness into chronic disease care programs may mitigate mortality risks.

The Guangxi outbreak highlights the evolving threat of H7N9, particularly its transition to HPAI. Sustained vigilance, intersectoral collaboration, and adaptive strategies remain paramount to preventing future epidemics.

doi.org/10.1097/CM9.0000000000000376

Was this helpful?

0 / 0